The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 39 | — | 20.1x | Near average | |
Growth | 83 | — | 5.6% | Above average | |
Quality | 95 | 81.1% | 7.6% | Above average | |
Safety | 28 | 2.1x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Kalaris Therapeutics Inc is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Kalaris Therapeutics Inc shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The data shows complete stability in the average price target at 18.25 dollars over the past thirty days, with a wide gap (Dispersion) between the minimum of 14 dollars and the maximum of 23 dollars, reflecting varying estimates despite the limited number of analysts (only two analysts). The stock is currently trading at 4.92 dollars, representing a significant discount from the target price, but this optimism is offset by a total absence of expected revenue for 2024 and 2025.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.